Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Jardiance Will Come Back as No. 1 in Japan SGLT2 Space after CKD Launch: NBI Chair
Nippon Boehringer Ingelheim’s Jardiance (empagliflozin) fell to the second spot in the Japanese SGLT2 market in 2021, but its planned label expansion into chronic kidney disease (CKD) will help it retrieve the No. 1 crown, Chairman and President Yoshiaki Aono…
To read the full story
Related Article
- Nippon Boehringer Ingelheim Logs 6.7% Sales Rise in 2021
April 19, 2022
- Jardiance, Ofev Drive Up Boehringer’s Japan Sales in 2021
April 6, 2022
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Yoshiaki Aono to Be Promoted to Chairman and President of Nippon BI in September
July 10, 2020
BUSINESS
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
- Novartis, JSH Begin Project to Address Regional Gaps in Hematology Care
April 14, 2026
- Nxera to Receive US$22.5 Million Milestone as Schizophrenia Drug Enters PII
April 14, 2026
- Itochu Unit to Import Sodium, Potassium Chloride from Germany
April 14, 2026
- JCR Launches PIII Dose Comparison Study of Growject in Japan
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…